跳至主要内容
临床试验/NCT06393309
NCT06393309已完成不适用

Investigation of Long-term Outcome of Levetiracetam and Valproate in Treatment of Idiopathic Generalized Epilepsy

Mazandaran University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 169 人开始时间: 2022年9月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
169
试验地点
1
主要终点
Seizure free rate

研究概览

简要总结

This study aimed to compare the long-term efficacy and safety of levetiracetam and valproate in treatment of idiopathic generalized epilepsy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of juvenile myoclonic epilepsy or generalized tonic-clonic seizure alone
  • Regular monotherapy with levetiracetam or sodium valproate

排除标准

  • Poor drug adherence
  • Pregnancy

研究组 & 干预措施

Sodium valproate

Patients with idiopathic generalized epilepsy who were under treatment with valproate

干预措施: Sodium valproate (Drug)

Levetiracetam

Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam

干预措施: Levetiracetam (Drug)

结局指标

主要结局

Seizure free rate

时间窗: 1 to 5 years

The percent of patients who remained seizure free on treatment

Time to first seizure

时间窗: 1 to 5 years

The interval between start of treatment and recurrence of seizure

次要结局

  • Retention rate(1 to 5 years)
  • Time to withdrawal(1 to 5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nasim Tabrizi

Associate professor of neurology

Mazandaran University of Medical Sciences

研究点 (1)

Loading locations...

相似试验